Promising work, especially in light of FDA-approved AAV gene therapy entering the U.S. market early this year to restore vision in patients diagnosed with biallelic RPE65-mutation-associated retinal dystrophy.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us